Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


AstraZeneca Breast Cancer Study Locator Service 1-877-400-4655
az-bcsl@careboxhealth.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Back

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Recruiting

Open to: ALL

Age: 18.0 - 130.0

Cambridge Manchester Sutton London London Edinburgh Brighton Ipswich Peterborough Oxford Stoke on Trent Guildford Derby Burton-on-Trent Keighley

Medical Conditions

Breast Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2023 Apr 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Camizestrant. Experimental. Administered orally

Intervention Arm Group : Arm B: camizestrant;

Intervention Type : DRUG
Intervention Description : Tamoxifen. Comparator. Administered per local approved label

Intervention Arm Group : Arm A: standard endocrine therapy of investigator´s choice;

Intervention Type : DRUG
Intervention Description : Anastrozole. Comparator. Administered per local approved label

Intervention Arm Group : Arm A: standard endocrine therapy of investigator´s choice;

Intervention Type : DRUG
Intervention Description : Letrozole. Comparator. Administered per local approved label

Intervention Arm Group : Arm A: standard endocrine therapy of investigator´s choice;

Intervention Type : DRUG
Intervention Description : Exemestane. Comparator. Administered per local approved label

Intervention Arm Group : Arm A: standard endocrine therapy of investigator´s choice;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Cambridge
    CB2 0QQ
  • Research Site
    Manchester
    M20 4BX
  • Research Site
    Sutton
    SM2 5PT
  • Research Site
    London
    SW3 6JJ
  • Research Site
    London
    SE1 9RT
  • Research Site
    Edinburgh
    EH4 2XU
  • Research Site
    Brighton
    BN2 5BE
  • Research Site
    Ipswich
    IP4 5PD
  • Research Site
    Peterborough
    PE3 9GZ
  • Research Site
    Oxford
    OX3 7LJ
  • Research Site
    Stoke on Trent
    ST4 6QG
  • Research Site
    Guildford
  • Research Site
    Derby
    DE22 3NE
  • Research Site
    Burton-on-Trent
    DE13 0RB
  • Research Site
    Keighley
    BD20 6TD

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


AstraZeneca Breast Cancer Study Locator Service 1-877-400-4655
az-bcsl@careboxhealth.com



The study is sponsored by AstraZeneca




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05774951
Last updated 16 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top